Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
S. Van der Linden, D. Van der Heijden.
Classification of spondyloarthropathies.
Rheumatology, pp. 1149-1151
[2.]
M. Dougados, S.M. Van der Linden, R. Jhulin, B. Huitfeld, B. Amon, A. Colin, et al.
The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy.
Arthritis Rheum, 34 (1991), pp. 1218-1227
[3.]
B. Amor, M. Dougados, M. Mijiyawa.
Critères de classification des Spondylarthropathies.
Rev Rhum Mal Ost, 57 (1990), pp. 85-89
[4.]
J. Braun, M. Bollow, Remliger G. Eggens, Rudwaleit M. Distler, et al.
Prevalence of spondyloarthropathies in HLA-B27 positive and negative blood donnors.
Arthritis Rheum, 41 (1998), pp. 58-67
[5.]
J.T. Gran, G. Husby.
The epidemiology of ankylosing spondylitis.
Semin Arthritis Rheum, 22 (1993), pp. 319-334
[6.]
J. Braun, T. Pincus.
Mortality, course of disease and prognosis of patients with ankylosing spondylitis.
Clin Exp Rheumatol, 20 (2002), pp. S16-22
[7.]
L. Koehler, J.G. Kuipers, H. Zeidler.
Managing seronegative spondarthritides.
Rheumatology, 39 (2000), pp. 360-368
[8.]
D.O. Clegg, D.J. Reda, M. Abdellatif.
Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: a Department of Veterans Affairs cooperative study.
Arthritis Rheum, 42 (1999), pp. 2325-2329
[9.]
P.J. Mease.
Recent advances in the management of psoriatic arthritis.
Curr Opin Rheumatol, 16 (2004), pp. 366-370
[10.]
D. Van der Heijde, B. Dijkmans, P. Geusens, J. Sieper, K. Dewoody, P. Williamson, et al.
Efficacy and safety of infliximab in patients with spondylitis: results of a randomized, placebo-controlled trial (ASSERT).
Arthritis Rheum, 52 (2005), pp. 582-591
[11.]
J.D. Gorman, K.E. Sack, J.D. Davis.
Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor α.
N Engl J Med, 346 (2002), pp. 1349-1356
[12.]
A. Calin, B.A. Dijkmans, P. Emery, M. Hakala, J. Kalden, M. Leirisalo-Repo, et al.
Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis.
Ann Rheum Dis, 63 (2004), pp. 1594-1600
[13.]
Antoni CE, Krueger GC, De Vlam K, Birba C, Beutler A, Guzzo C, et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis. Published Online First January 27th, 2005.doi:10.1136/ard.2004.032268.
[14.]
P.J. Mease, B.S. Goffe, J. Metz, A. VanderStoep, B. Finck, D.J. Burge.
Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial.
Lancet, 356 (2000), pp. 385-390
[15.]
V. Rodríguez-Valverde, J.M. Álvaro-Gracia, J.L. Andreu, J. Batlle, J. Tornero.
Segunda actualización del consenso de la Sociedad Española de Reumatología sobre la terapia biológica en artritis reumatoide.
Rev Esp Reumatol, 31 (2004), pp. 394-401
[16.]
L. Heuft-Dorenbosch, A. Van Tubergen, A. Spoorenberg, R. Landewe, M. Dougados, H. Mielants, et al.
The influence of peripheral arthritis on disease activity in ankylosing spondylitis patients as measured with the Bath Ankylosing Spondylitis Disease Activity Index.
Arthritis Rheum, 51 (2004), pp. 154-159
[17.]
S.L. Garret, T.R. Jenkinson, H.C. Whitelock, L.G. Kennedy, G. Gainsford, A. Calin.
A new approach to defining disease status in ankylosing spondylitis. The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI).
J Rheumatol, 21 (1994), pp. 2286-2291
[18.]
R. Ariza-Ariza, B. Hernández-Cruz, F. Navarro-Sarabia.
La versión española del BASDAI es fiable y se correlaciona con la actividad de la enfermedad en pacientes con espondilitis anquilosante.
Rev Esp Reumatol, 31 (2004), pp. 372-378
[19.]
M.A. Stone, R.D. Inman, J.G. Wright, A. Maetzel.
Validation exercise of the Ankylosing Spondylitis Assessment Study (ASAS) group response criteria in ankylosing spondylitis patients treated with biologics.
Arthritis Rheum, 51 (2004), pp. 316-320
[20.]
A. Calin, S. Garrett, H. Whitelock, L.G. Kennedy, A.J. O’Hea, P. Mallorie, et al.
A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index.
J Rheumatol, 21 (1994), pp. 2281-2285
[21.]
J.J. Anderson, G. Baron, D. Van der Heijde, D.T. Nelson, M. Dougados.
Ankylosing spondylitis assessment group preliminary definition of shortterm improvement in ankylosing spondylitis.
Arthritis Rheum, 44 (2001), pp. 1876-1886
[22.]
J.E. Gottenberg, F. Merle-Vicent, F. Bentaberry, Y. Allanore, F. Berenbaum, B. Fautrel, et al.
Anti-tumor necrosis factor alpha therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides: a follow-up report of tolerability and efficacy.
Arthritis Rheum, 48 (2003), pp. 2019-2024
[23.]
J.T. Rosenbaum, J.R. Smith.
Anti-TNFá therapy for eye involvement in spondyloarthropathy.
Clin Exp Rheumatol, 20 (2002), pp. S143-S145
[24.]
A.L. Tan, H. Marzo-Ortega, P. O’Connor, A. Fraser, P. Emery, D. McGonagle.
Efficacy of anakinra in active ankylosing spondylitis: a clinical and magnetic resonance imaging study.
Ann Rheum Dis, 63 (2004), pp. 1041-1045
[25.]
A.L. Chew, A. Bennett, C.H. Smith, J. Barker, B. Kirkham.
Successful treatment of severe psoriasis and psoriasis arthritis with adalimumab.
Br J Dermatol, 151 (2004), pp. 492-496
[26.]
M. Dougados, J.M. Behier, I. Jolchine, A. Calin, D. Van der Heijde, I. Olivieri, et al.
Efficacy of celecoxib, a ciclooxygenase 2-specific inhibitor, in the treatment of ankylosing spondylitis: a six-week controlled study with comparison against placebo and against a conventional nonsteroidal anti-inflammatory drug.
Arthritis Rheum, 44 (2001), pp. 180-185
[27.]
D. Van der Heijde, H.S.B. Baraf, C. Ramos-Remus, A. Colin, A.L. Weaver, M. Schiff, et al.
Evaluation of the efficacy of eterocoxib in ankylosing spondylitis.
Arthristis Rheum, 52 (2005), pp. 1205-1215
[28.]
M. Abu-Shakra, D.D. Gladman, J.C. Thorne, J. Long, V.T. Farewell.
Longterm methotrexate therapy in psoriatic arthritis: clinical and radiological outcome.
J Rheumatol, 22 (1995), pp. 241-245
[29.]
M. Dougados, S. Van der Linden, M. Leirisalo-Repo, B. Huitfeldt, R. Juhlin, E. Veys, et al.
Sulfasalazine in the treatment of spondylarthropathy. A randomized, multicenter, double-blind, placebo-controlled study.
Arthritis Rheum, 38 (1995), pp. 618-627
[30.]
J.P. Kaltwasser, P. Nash, D. Gladman, C.F. Rosen, F. Behrens, P. Jones, et al.
Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial.
Arthritis Rheum, 50 (2004), pp. 1939-1950
[31.]
A.D. Fraser, A.W. Van Kuijk, R. Westhovens, Z. Karim, R. Wakefield, A.H. Gerards, et al.
A randomised, double-blind, placebo controlled, multicentre trial of combination therapy with methotrexate plus cyclosporin in patients with active psoriatic arthritis.
Ann Rheum Dis, (2005),
[32.]
J. Sieper, C. Fendler, S. Laitko, H. Sorensen, C. Gripenberg-Lerche, F. Hiepe, et al.
No benefit of long-term ciprofloxacin treatment in patients with reactive arthritis and undifferentiated oligoarthritis: a three-month, multicenter, double-blind, randomized, placebo-controlled study.
Arthritis Rheum, 42 (1999), pp. 1386-1396
[33.]
D. Wakefield, P. McCluskey, M. Verma, K. Aziz, B. Gatus, G. Carr.
Ciprofloxacin treatment does not influence course or relapse rate of reactive arthritis and anterior uveitis.
Arthritis Rheum, 42 (1999), pp. 1894-1897
[34.]
M. Smieja, D.W. MacPherson, W. Kean, M.L. Schmuck, C.H. Goldsmith, W. Buchanan, et al.
Randomised, blinded, placebo controlled trial of doxycycline for chronic seronegative arthritis.
Ann Rheum Dis, 60 (2001), pp. 1088-1094
[35.]
W.P. Maksymowych, G.S. Jhangri, A.A. Fitzgerald, S. LeClercq, P. Chiu, A. Yan, et al.
A six-month randomized, controlled, double-blind, doseresponse comparison of intravenous pamidronate (60 mg versus 10 mg) in the treatment of nonsteroidal antiinflammatory drug-refractory ankylosing spondylitis.
Arthritis Rheum, 46 (2002), pp. 766-773
[36.]
H. Haibel, J. Brandt, M. Rudwaleit, H. Soerensen, S. Sieper, J. Braun.
Treatment of active ankylosing spondylitis with pamidronate.
Rheumatology, 42 (2003), pp. 1018-1020
[37.]
F. Van den Bosch, E. Kruithof, D. Baeten, A. Herssens, F. De Keyser, H. Mielants, et al.
Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondylarthropathy.
Arthritis Rheum, 46 (2002), pp. 755-765
[38.]
O.N. Pamuk, O. Harmandar, B. Tosun, Y. Yoruk, N. Cakir.
A patient with ankylosing spondylitis who presented with chronic necrotising aspergillosis. Report on one case and review of the literature.
Clin Rheumatol. En prensa, (2005),
[39.]
D. Baeten, E. Kruithof, F. Van den Bosch, N. Van den Bossche, A. Herssens, H. Mielants, et al.
Systematic safety follow up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: a new perspective on the role of host defence in the pathogenesis of the disease?.
Ann Rheum Dis, 62 (2003), pp. 829-834
[40.]
C. Ferraro-Peyret, F. Coury, J.G. Tebib, J. Bienvenu, N. Fabien.
Infliximab therapy in rheumatoid arthritis and ankylosing spondylitis-induced specific antinuclear and antiphospholipid autoantibodies without autoimmune clinical manifestations: a two-year prospective study.
Arthritis Res Ther, 6 (2004), pp. 535-543
Al final del manuscrito se ofrece la relación de miembros del Panel de Expertos de la SER.
Copyright © 2005. Elsevier España S.L. Barcelona
